DBL™ Bleomycin Sulphate ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

dbl™ bleomycin sulphate

pfizer new zealand limited - bleomycin sulfate 15000 [iu];   - powder for injection - 15000 iu - active: bleomycin sulfate 15000 [iu]   excipient: water for injection - dbl™ bleomycin sulfate for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents; squamous cell carcinoma: head and neck including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingiva, epiglottis, skin, larynx, penis, cervix, and vulva. the response to bleomycin sulfate is poorer in patients with head and neck cancer previously irradiated.

DAIVOBET 50/500 calcipotriol 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g gel bottle オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

daivobet 50/500 calcipotriol 50 microgram/g and betamethasone (as dipropionate) 500 microgram/g gel bottle

leo pharma pty ltd - calcipotriol, quantity: 50 microgram/g; betamethasone dipropionate (equivalent: betamethasone, qty 500 microgram/g) - gel - excipient ingredients: nitrogen; hydrogenated castor oil; polyoxypropylene-11 stearyl ether; butylated hydroxytoluene; liquid paraffin; dl-alpha-tocopherol - topical treatment of scalp psoriasis. topical treatment of mild to moderate plaque psoriasis on the body in adults.

PROTOPIC- tacrolimus ointment アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

protopic- tacrolimus ointment

leo pharma inc - tacrolimus (unii: wm0haq4wnm) (tacrolimus anhydrous - unii:y5l2157c4j) - tacrolimus anhydrous 0.3 mg in 1 g - protopic® ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy  for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. protopic® ointment is not indicated for children younger than 2 years of age (see boxed warning, warnings and precautions: pediatric use). protopic® ointment is contraindicated in patients with a history of hypersensitivity to tacrolimus or any other component of the ointment.

FUCIDIN sodium fusidate 20mg/g ointment tube オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

fucidin sodium fusidate 20mg/g ointment tube

leo pharma pty ltd - sodium fusidate, quantity: 20 mg/g - ointment - excipient ingredients: white soft paraffin; cetyl alcohol; wool fat; liquid paraffin - skin lesions primarily and secondarily infected with staphylococci, e.g. abscesses, boils, furunculosis, impetigo, folliculitis, hidradenitis, pyoderma, sycosis barbae, otitis externa.

Nerisone ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

nerisone

leo pharma limited - diflucortolone valerate 0.1% - topical cream - 0.1 % - active: diflucortolone valerate 0.1% excipient: carbomer disodium edetate dihydrate liquid paraffin macrogol stearate 2000 methyl hydroxybenzoate propyl hydroxybenzoate purified water sodium hydroxide stearyl alcohol white soft paraffin - all skin diseases which respond to topical corticoid therapy (eg): contact dermatitis, contact eczema, occupational eczema vulgar, nummular, degenerative and seborrhoeic eczema, dyshidrotic eczema, eczema in varicose syndrome (but not directly onto lower limb ulcers), anal eczema, eczema in children, neurodermatitis (endogenous eczema, atopic dermatitis), psoriasis, lichen ruber planus et verrucosus, lupus erythematosus discoides, first degree burns, sunburn, insect bites.

Nerisone Fatty ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

nerisone fatty

leo pharma limited - diflucortolone valerate 0.1% - topical ointment - 0.1 % - active: diflucortolone valerate 0.1% excipient: hydrogenated castor oil liquid paraffin microcrystalline wax white soft paraffin - all skin diseases which respond to topical corticoid therapy (eg): contact dermatitis, contact eczema, occupational eczema vulgar, nummular, degenerative and seborrhoeic eczema, dyshidrotic eczema, eczema in varicose syndrome (but not directly onto lower limb ulcers), anal eczema, eczema in children, neurodermatitis (endogenous eczema, atopic dermatitis), psoriasis, lichen ruber planus et verrucosus, lupus erythematosus discoides, first degree burns, sunburn, insect bites.